Literature DB >> 10597097

Electrocardiography in the patient with the Wolff-Parkinson-White syndrome: diagnostic and initial therapeutic issues.

M H Rosner1, W J Brady, M P Kefer, M L Martin.   

Abstract

The Wolff-Parkinson-White syndrome (WPW), estimated to occur in approximately 0.1% to 3% of the general population, is a form of ventricular preexcitation involving an accessory conduction pathway. The definition of WPW relies on the following electrocardiographic features: (1) a PR interval less than 0.12 seconds (2) with a slurring of the initial segment of the QRS complex, known as a delta wave, (3) a QRS complex widening with a total duration greater than 0.12 seconds, and (4) secondary repolarization changes reflected in ST segment-T wave changes that are generally directed opposite (discordant) to the major delta wave and QRS complex changes. The accessory pathway bypasses the atrioventricular (AV) node, creating a direct electrical connection between the atria and ventricles. The majority of patients with preexcitation syndromes remain asymptomatic throughout their lives. When symptoms do occur they are usually secondary to tachyarrhythmias; the importance of recognizing this syndrome is that these patients may be at risk to develop a variety of supraventricular tachyarrhythmias which cause disabling symptoms and, in the extreme, sudden cardiac death. The tachyarrhythmias encountered in the WPW patient include paroxysmal supraventricular tachycardia (both the narrow QRS and wide QRS complex varieties), atrial fibrillation, atrial flutter, and ventricular fibrillation. Diagnostic and urgent, initial therapeutic issues based on initial electrocardiographic information are presented via 5 illustrative cases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597097     DOI: 10.1016/s0735-6757(99)90167-5

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  9 in total

Review 1.  AMPK in cardiovascular health and disease.

Authors:  Najeeb A Shirwany; Ming-Hui Zou
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

2.  Probable association of tachyarrhythmia with nebulized albuterol in a child with previously subclinical wolff Parkinson white syndrome.

Authors:  Michiel Kroesen; Machiel Maseland; Jaime Smal; Annet Reimer; Petra van Setten
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

3.  Anaesthetic management of a case of Wolff-Parkinson-White syndrome.

Authors:  Savitri D Kabade; Safiya Sheikh; Bhavya Periyadka
Journal:  Indian J Anaesth       Date:  2011-07

4.  Anesthetic management in a patient with Wolff-Parkinson-White syndrome for laparoscopic cholecystectomy.

Authors:  Anurag Gupta; Jyoti Sharma; Neerja Banerjee; Rajesh Sood
Journal:  Anesth Essays Res       Date:  2013 May-Aug

5.  Assessment of atrial fibrillation and vulnerability in patients with Wolff-Parkinson-White syndrome using two-dimensional speckle tracking echocardiography.

Authors:  Jing-Jie Li; Fang Wei; Ju-Gang Chen; Yan-Wei Yu; Hong-Yue Gu; Rui Jiang; Xiu-Li Wu; Qian Sun
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

6.  Sudden cardiac arrest due to coronary vasospasm in a patient with Wolff-Parkinson-White syndrome during brain surgery: a case report.

Authors:  Yuka Matsuki; Maki Mizogami; Kenji Shigemi
Journal:  JA Clin Rep       Date:  2019-02-28

7.  Anesthetic Management of a Patient with Wolff-Parkinson-White Syndrome for Laparoscopic Cholecystectomy: A Case Report.

Authors:  Kiran Kumar Kc; Sundar Hyoju; Pawan Kumar Raya
Journal:  JNMA J Nepal Med Assoc       Date:  2020-09-27       Impact factor: 0.406

8.  A serious cause of panic attack.

Authors:  Michael O'Connell; Aaron Bernard
Journal:  Case Rep Emerg Med       Date:  2012-06-12

Review 9.  Natural AMPK Activators in Cardiovascular Disease Prevention.

Authors:  Reza Heidary Moghaddam; Zeinab Samimi; Sedigheh Asgary; Pantea Mohammadi; Soroush Hozeifi; Fatemeh Hoseinzadeh-Chahkandak; Suowen Xu; Mohammad Hosein Farzaei
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.